Clinical Advisory Board
David S. Boyer, M.D.
Dr. Boyer is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. He is Senior Partner at Retina-Vitreous Associates Medical Group with six offices in California. Dr. Boyer is a Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA. He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. A widely-published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases.
Frederick L. Ferris III, M.D.
Dr. Ferris started his career at the National Eye Institute (NEI), National Institutes of Health in 1973. He was the Director of the Division of Epidemiology and Clinical Applications at NEI from 1994 to 2017 and was the Clinical Director at NEI from 2000 to 2017. He received an A.B. degree from Princeton University in 1968 and completed his medical training, internship and ophthalmology residency at Johns Hopkins. He is a board-certified ophthalmologist and epidemiologist. He has published over 300 manuscripts in peer review journals and has been involved in dozens of national and international clinical trials.
Thomas Hohman, PhD
Dr. Hohman was formerly Head of Retina Discovery and Vice President of Retina Translation Medicine at Allergan, where he was responsible for discovering and advancing new treatments for retinal diseases. Prior to retiring, his efforts at Allergan focused on identifying biomarkers and methods quantifying retina functional changes that predict disease progression. These efforts formed the basis for clinical interventional studies of novel treatments for exudative age-related macular degeneration and geographic atrophy. Prior to his tenure at Allergan, Dr Hohman held leadership positions at Alcon Research as VP of Retinal Research and Development, and at Novartis as Disease area Section Head for Ophthalmology Clinical Research and Development.